Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes - Concepedia

Concepedia

Publication | Open Access

Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes

DOI Full Paper Access

139

Citations

21

References

2012

Year

Anas Younes, Jorge Romaguera, Michelle A. Fanale, Peter McLaughlin, Frederick Hagemeister, Amanda Copeland, Sattva S. Neelapu, Larry W. Kwak, Jatin J. Shah, Silvana de Castro Faria,

Journal of Clinical Oncology

Abstract

SB1518 has encouraging activity in relapsed lymphoma, providing the first proof-of-principle of the potential therapeutic value of targeting the JAK/STAT pathway in lymphoma in the clinical setting.

References

	Year	Citations

Page 1